• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
Catholic Review

Catholic Review

Inspiring the Archdiocese of Baltimore

Menu
  • Home
  • News
        • Local News
        • World News
        • Vatican News
        • Obituaries
        • Featured Video
        • En Español
        • Sports News
        • Official Clergy Assignments
        • Schools News
  • Commentary
        • Contributors
          • Question Corner
          • George Weigel
          • Elizabeth Scalia
          • Michael R. Heinlein
          • Effie Caldarola
          • Guest Commentary
        • CR Columnists
          • Archbishop William E. Lori
          • Rita Buettner
          • Christopher Gunty
          • George Matysek Jr.
          • Mark Viviano
          • Father Joseph Breighner
          • Father Collin Poston
          • Amen Columns
  • Entertainment
        • Events
        • Movie & Television Reviews
        • Arts & Culture
        • Books
        • Recipes
        • CR Kids
  • About Us
        • Contact Us
        • Our History
        • Meet Our Staff
        • Photos to own
        • Shop
        • CR Media platforms
        • Electronic Edition
        • Subscribe
  • Advertising
  • Kids
  • News Tips
  • Radio/Podcasts
        • Catholic Review Radio
        • Protagonistas de Fe
        • In God’s Image
        • “In Charity and Truth” with Archbishop William E. Lori
  • Subscribe
Mifepristone, the first medication in a chemical abortion, is prepared for a patient at Alamo Women's Clinic in Carbondale, Ill., April 20, 2023. The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug's availability. (OSV News photo/Evelyn Hockstein)

Supreme Court is asked to weigh in on future of abortion pill

September 13, 2023
By Kate Scanlon
OSV News
Filed Under: Feature, News, Respect Life, Supreme Court, World News

WASHINGTON (OSV News) — The Justice Department and the manufacturer of an abortion drug asked the U.S. Supreme Court Sept. 8 to overturn a lower-court ruling that would limit access to the drug, setting the stage for the high court to weigh in on the future of the drug’s availability.

A coalition of pro-life opponents of mifepristone, the first of two drugs used in a medication or chemical abortion, previously filed suit in an effort to revoke the U.S. Food and Drug Administration’s approval of the drug, arguing the government violated its own safety standards when it first approved the drug in 2000.

However, proponents argued mifepristone poses statistically little risk to women using it for abortion early in pregnancy and claim the drug is being singled out for political reasons.

In its filing on behalf of the FDA, the Justice Department called the appeals court ruling an “unprecedented decision,” arguing its logic “would threaten to severely disrupt the pharmaceutical industry and prevent FDA from fulfilling its statutory responsibilities according to its scientific judgment.”

The filing argued the drug is safe and that “study after study” has shown “serious adverse events are exceedingly rare” when mifepristone is taken under the approved conditions. The filing added, “For many patients, mifepristone is the best method to lawfully terminate their early pregnancies.”

It stated that revoking approval of the pill “would be damaging for women and health care providers around the Nation.”

But in a statement, Erik Baptist, senior counsel for Alliance Defending Freedom, which is representing the pro-life coalition challenging mifepristone’s approval, said the FDA “has been entrusted to serve as the nation’s gatekeeper of legal drugs.”

“By repeatedly and unlawfully removing critical safeguards in the chemical abortion regimen, the FDA has failed to protect the safety of women and girls,” he said. “Two courts have now held the FDA accountable for the damage it has done to the rule of law and the harm it has caused to countless girls and women. We hope the Supreme Court does the same.”

Earlier this year, the Supreme Court blocked a lower court’s restrictions on mifepristone, leaving the abortion pill on the market while litigation proceeds. That decision froze the lower court’s ruling to stay the FDA’s approval of the drug.

The Justice Department and Danco, the pharmaceutical company that manufactures mifepristone, previously asked the Supreme Court to intervene in the case after an appeals court allowed portions of the ruling by U.S. District Judge Matthew Kacsmaryk to take effect.

In a Sept. 8 statement, Danco said it “continues to be at the forefront of this fight and is working closely with the reproductive rights community and pharmaceutical industry to support the changes made by FDA.”

Should the Supreme Court take the case, it would likely be added to its docket in its coming term.

The two-drug chemical abortion regimen is currently legal in some form in 36 states and the District of Columbia. It is permitted in 21 states, but with some additional restrictions in the remaining 15, according to data from the Guttmacher Institute, which supports abortion access.

The Catholic Church opposes abortion, teaching that all human life is sacred from conception to natural death and that society must extend support to mothers and children. Earlier this year, Bishop Michael F. Burbidge of Arlington, chairman of the U.S. Conference of Catholic Bishops’ Committee on Pro-Life Activities, denounced Biden administration’s attempts to loosen regulations around the abortion bill, saying the U.S. bishops “decry the continuing push for the destruction of innocent human lives and the loosening of vital safety standards for vulnerable women.”

A link to the Justice Department’s filing is here: https://s3.documentcloud.org/documents/23945337/usfda-et-al-v-alliance-for-hippocratic-medicine-et-al-petition.pdf.

Read More Respect Life

‘Remarkable victory’: Life advocates welcome defeat of assisted suicide bill in England and Wales

Judge shields more Catholic health providers as Illinois assisted suicide law takes effect

Housing, gender, abortion policies among state ballot measures in 2026

Cardinal Cupich, women religious, Catholic pharmacist sue Illinois over assisted suicide law

Scottish school settles case with Catholic teacher fired after abortion discussion

Cassidy takes aim at FDA mifepristone regulation, manufacturers

Copyright © 2023 OSV News

Print Print

Primary Sidebar

Kate Scanlon

Click here to view all posts from this author

For the latest news delivered twice a week via email or text message, sign up to receive our free enewsletter.

| MOST POPULAR |

  • 5 things to know about Archbishop Fulton Sheen as his beatification approaches
  • St. Francis of Assisi in Fulton rededicated
  • Archbishop Lori urges women religious to model renewal of American political culture 
  • St. Bernadette’s relics draw hundreds of pilgrims to Emmitsburg despite heavy rain 
  • Lourdes fully covers Rupnik mosaics ahead of Pope Leo visit, citing care for abuse survivors

| Latest Local News |

St. Bernadette’s relics draw hundreds of pilgrims to Emmitsburg despite heavy rain 

Radio Interview: Archbishop Fulton Sheen’s enduring legacy

Nurses at Ascension St. Agnes Hospital approve contract

St. Francis of Assisi in Fulton rededicated

Archbishop Lori urges women religious to model renewal of American political culture 

| Latest World News |

Technological advancements are not rivals to faith, pope says

Sheen beatification ‘a gift’ and a call to mission, say pilgrims in St. Louis

‘Pivotal’ Archbishop Sheen ‘opened the door to the evangelization of the world,’ says Bishop Barron

Canadian Catholics stand with Jewish brethren following synagogue attack in Ontario

Trump tells UN he may opt to ‘annihilate’ Iran, will rebrand AI ‘superintelligence’

| Catholic Review Radio |

Footer

Our Vision

Real Life. Real Faith. 

Catholic Review Media communicates the Gospel and its impact on people’s lives in the Archdiocese of Baltimore and beyond.

Our Mission

Catholic Review Media provides intergenerational communications that inform, teach, inspire and engage Catholics and all of good will in the mission of Christ through diverse forms of media.

Contact

Catholic Review
320 Cathedral Street
Baltimore, MD 21201
443-524-3150
mail@CatholicReview.org

 

Social Media

  • Facebook
  • Instagram
  • Twitter
  • YouTube

Recent

  • Technological advancements are not rivals to faith, pope says
  • Sheen beatification ‘a gift’ and a call to mission, say pilgrims in St. Louis
  • ‘Pivotal’ Archbishop Sheen ‘opened the door to the evangelization of the world,’ says Bishop Barron
  • Canadian Catholics stand with Jewish brethren following synagogue attack in Ontario
  • Trump tells UN he may opt to ‘annihilate’ Iran, will rebrand AI ‘superintelligence’
  • Pope Leo XIV to make historic first veneration of ‘holy tunic,’ highlighting Christian unity
  • Canonization cause officially opens for pioneering Minnesota priest
  • Question Corner: Is it appropriate to hold hands or lift your hands up during the Our Father at Mass?
  • Pope, other world faith leaders urged to save starving Ukrainian victims of Russian blockade

Search

Membership

Catholic Media Assocation

Maryland-Delaware-DC Press Association

The Associated Church Press

© 2026 CATHOLIC REVIEW MEDIA, ALL RIGHTS RESERVED